Demplatin pegraglumer is under clinical development by NanoCarrier and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Demplatin pegraglumer’s likelihood of approval (LoA) and phase transition for Metastatic Biliary Tract Cancer took place on 05 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Demplatin pegraglumer Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Demplatin pegraglumer overview
Demplatin pegraglumer (Cisplatin, NC-6004, Nanoplatin) is under development for the treatment of squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, metastatic biliary tract cancer, bile duct cancer, bladder cancer, transitional cell carcinoma of the urinary tract, metastatic pancreatic cancer and recurrent head and neck squamous cell carcinoma. The drug candidate is administered intravenously. It acts by inhibiting DNA synthesis. The drug candidate is developed based on micellar nanoparticles technology. The formulation contains micellar nanoparticles of cisplatin derivatives.
NanoCarrier is a drug development company that develops and produces pharmaceuticals using micellar nanoparticles technology. The company’s pipeline products include NC-6004, VB-111, ENT103, NC-6004, NC-6300, NC-6100, TUG1 and RUNX1. NanoCarrier’s NC-6004 is used for the treatment for pancreatic cancer, head and neck cancer, bladder cancer, and biliary tract cancer. The company’s VB-111 is used for the treatment of recurrent glioblastoma, ovarian cancer and thyroid cancer. Its micellar nanoparticle technology is also used in developing cosmetics and healthcare products. The company operates its laboratory in Kanagawa, Japan. NanoCarrier is headquartered in Tokyo, Japan.
Quick View Demplatin pegraglumer LOA Data
|Highest Development Stage|